Article Text

Download PDFPDF
Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease
  1. Masahiko Shimura,
  2. Kanako Yasuda
  1. Correspondence to Dr Masahiko Shimura, Department of Ophthalmology, NTT East Japan Tohoku Hospital, 2-29-1, Yamato-machi, Wakabayashi, Sendai, Miyagi 984-8560, Japan; masahiko{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Recently, there have been several reports concerning the efficacy of intravitreal bevacizumab injection (IVB) in reducing macular oedema in patients with retinal vein occlusion (RVO).1 2 According to a safety survey of IVB, adverse ocular events are extremely rare.3 At our clinic, we have performed more than 300 IVB for RVO, and the majority of these injections did not have any adverse results. However, we experienced two cases of progression of macular ischaemia despite an improvement in macular oedema after IVB for central retinal vein occlusion (CRVO) in patients with poor glycaemic control of their diabetes and a history of systemic vascular disease.

Case report

Case 1

A 76-year-old female with diabetes for 26 years, without a history of retinopathy, presented with CRVO in the right eye (figure 1A) and no retinopathy in the left eye. She was treated with insulin, but had poor glycaemic control (HbA1c 9.6%). General blood examination revealed mild renal dysfunction (BUN: …

View Full Text


  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Institutional Review Board of NTT East Japan Tohoku Hospital Clinical Research Ethics Committee.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.